<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="852">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 29, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346628</url>
  </required_header>
  <id_info>
    <org_study_id>56032</org_study_id>
    <nct_id>NCT04346628</nct_id>
  </id_info>
  <brief_title>Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19</brief_title>
  <official_title>A Phase 2 Randomized, Open Label Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of oral favipiravir compared with SOC
      in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated
      COVID-19 disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to received either favipiravir + Standard of Care (SOC) or SOC alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time until cessation of oral shedding of SARS-CoV-2 virus</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Time in days from randomization to a negative result of nasopharyngeal and/or oropharyngeal and/or salivary swab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of participants with clinical worsening of COVID-19 disease</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Clinical worsening will be determined by clinician assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sars-CoV-2 viral load</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Viral load will be assessed as the TCID50 (Median Tissue Culture Infectious Dose) over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of participants with development of SARS-CoV-2 antibodies</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until cessation of symptoms</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of favipiravir</measure>
    <time_frame>Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)</time_frame>
    <description>Cmax is a pharmacokinetic parameter that measures the maximum concentration of drug in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of favipiravir</measure>
    <time_frame>Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)</time_frame>
    <description>Cmin is a pharmacokinetic parameter that measures the minimum concentration of drug in plasma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Favipiravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive favipiravir for 10 days plus standard of care treatment for COVID-19 infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive standard of care treatment for COVID-19 infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).</description>
    <arm_group_label>Favipiravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care treatment</intervention_name>
    <description>Standard of care treatment for COVID-19 infection</description>
    <arm_group_label>Favipiravir</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with laboratory confirmation of infection with SARS-CoV-2 and who are PCR
             positive (within five days or fewer prior to enrollment)

          -  Asymptomatic or mild respiratory disease, defined as a respiratory rate no more than
             20 breaths per minute and a normal oxygen saturation

          -  No more than four of the following of mild severity, and no more than two of moderate
             severity:

               -  Cough

               -  Sore throat

               -  Headache

               -  Nasal congestion

               -  Body aches and pains

               -  Fatigue

          -  Temperature less than 101 F

        Exclusion Criteria:

          -  Concomitant bacterial respiratory infection

          -  History of abnormalities of uric acid metabolism.

          -  History of hypersensitivity to an anti-viral nucleoside-analog drug targeting a viral
             RNA polymerase.

          -  Use of adrenocorticosteroids (except topical preparation or inhaled steroids) or
             immunosuppressive drugs (e.g., immunosuppressants, anticancer drugs)

          -  Serious chronic disease

          -  Previously received favipiravir.

          -  Renal insufficiency requiring hemodialysis or continuous ambulatory peritoneal
             dialysis (CAPD).

          -  Liver impairment greater than Child Pugh 1.

          -  History of alcohol or drug abuse in the previous two years

          -  Psychiatric disease that is not well controlled (controlled defined as stable on a
             regimen for more than one year)

          -  Patient has taken another investigational drug within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne (Bonnie) A Maldonado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Team</last_name>
      <phone>650-721-5805</phone>
      <email>altamira@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No current plan to share individual participant data (IPD).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

